Jacek Borawski

Summary

Affiliation: Medical University
Country: Poland

Publications

  1. ncbi Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers
    Jacek Borawski
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University, Bialystok, Poland
    Clin Appl Thromb Hemost 16:60-5. 2010
  2. ncbi Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Białystok, Poland
    Nephron 91:671-81. 2002
  3. ncbi [Periodontal disease and atherosclerosis: an underestimated link?]
    Magdalena Wilczynska-Borawska
    Zakład Stomatologii Zachowawczej Akademii Medycznej w Białymstoku
    Pol Merkur Lekarski 15:281-3. 2003
  4. ncbi Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical University, Białystok, Poland
    Kidney Int 64:2229-37. 2003
  5. ncbi Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin
    Jacek Borawski
    Department of Nephrology and Transplantology, Medical University, Białystok, Poland
    Am J Kidney Dis 47:37-41. 2006
  6. ncbi Serum alpha1-antitrypsin but not complement C3 and C4 predicts chronic inflammation in hemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Białystok, Poland
    Ren Fail 25:589-93. 2003
  7. ncbi The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients
    Jacek Borawski
    Department of Nephrology and Transplantology with Dialysis Unit, Medical University, 14 Zurawia Street, 15 540 Bialystok, Poland
    Nephrol Dial Transplant 22:457-64. 2007
  8. ncbi [SEN virus infection in maintenance hemodialysis patients]
    Jacek Borawski
    Kliniki Nefrologii i Transplantologii z Ośrodkiem Dializ Akademii Medycznej w Białymstoku
    Wiad Lek 59:751-6. 2006
  9. ncbi Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II
    Jacek Borawski
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University, Bialystok Poland
    J Nephrol 20:370-2. 2007
  10. ncbi Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland
    Clin Appl Thromb Hemost 8:359-67. 2002

Collaborators

Detail Information

Publications46

  1. ncbi Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers
    Jacek Borawski
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University, Bialystok, Poland
    Clin Appl Thromb Hemost 16:60-5. 2010
    ..Baseline cytokine levels decreased during the 2-week trial by more than 50%. In conclusion, transforming growth factor-beta1 release and likely downregulation of its expression may constitute novel pharmacological effects of sulodexide...
  2. ncbi Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Białystok, Poland
    Nephron 91:671-81. 2002
    ....
  3. ncbi [Periodontal disease and atherosclerosis: an underestimated link?]
    Magdalena Wilczynska-Borawska
    Zakład Stomatologii Zachowawczej Akademii Medycznej w Białymstoku
    Pol Merkur Lekarski 15:281-3. 2003
    ..It deserves timely treatment also as a likely part of primary prevention of ischemic heart disease, stroke, and peripheral vascular disease...
  4. ncbi Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical University, Białystok, Poland
    Kidney Int 64:2229-37. 2003
    ..We prospectively studied the effects of unfractionated heparin (UFH) versus low-molecular-weight heparin (LMWH) enoxaparin-anticoagulated hemodialysis on plasma levels of the cytokines...
  5. ncbi Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin
    Jacek Borawski
    Department of Nephrology and Transplantology, Medical University, Białystok, Poland
    Am J Kidney Dis 47:37-41. 2006
    ....
  6. ncbi Serum alpha1-antitrypsin but not complement C3 and C4 predicts chronic inflammation in hemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Białystok, Poland
    Ren Fail 25:589-93. 2003
    ..We studied whether predialysis serum levels of positive acute phase markers such as alpha1-antitrypsin (AT), and complement components C3 and C4 could identify the presence of chronic inflammation in maintenance hemodialysis (HD) patients...
  7. ncbi The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients
    Jacek Borawski
    Department of Nephrology and Transplantology with Dialysis Unit, Medical University, 14 Zurawia Street, 15 540 Bialystok, Poland
    Nephrol Dial Transplant 22:457-64. 2007
    ..Its extent in maintenance haemodialysis (HD) patients is disputable and not known in continuous ambulatory peritoneal dialysis (CAPD) and pre-dialysis chronic kidney disease (CKD) patients...
  8. ncbi [SEN virus infection in maintenance hemodialysis patients]
    Jacek Borawski
    Kliniki Nefrologii i Transplantologii z Ośrodkiem Dializ Akademii Medycznej w Białymstoku
    Wiad Lek 59:751-6. 2006
    ..Risk factors for its occurrence are equivocal; the infection may well be transmitted by parenteral and feco-oral routes. SEN virus is not directly responsible for liver damage in maintenance HD patients...
  9. ncbi Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II
    Jacek Borawski
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University, Bialystok Poland
    J Nephrol 20:370-2. 2007
    ..He was uneventfully treated with HD for 6 weeks and then reverted to CAPD. The widely available and inexpensive SLX may be a new, effective and potentially promising alternative anticoagulant in HD patients with HIT II...
  10. ncbi Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland
    Clin Appl Thromb Hemost 8:359-67. 2002
    ..Liver disease and use of erythropoietin treatment are also important determinants of these markers, and should be considered in further studies...
  11. ncbi Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Białystok, Poland
    Ren Fail 24:825-37. 2002
    ..We studied whether they could be associated with each other, SOX markers, prevalence of viral hepatitis, and cardiovascular disease (CVD) and their laboratory surrogates in maintenance hemodialysis (HD) patients...
  12. ncbi Tissue factor pathway inhibitor release and depletion by sulodexide in humans
    J Borawski
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland
    Adv Med Sci 54:32-6. 2009
    ..We investigated the effects of sulodexide--a commercially available mixture of heparan and dermatan sulfate, on plasma TFPI release and depletion...
  13. ncbi Endothelial injury markers with high-dose intravenous iron therapy in renal failure
    Jacek Borawski
    Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bialystok, Poland
    Clin Appl Thromb Hemost 10:403-6. 2004
    ..172); no thrombotic or other adverse effects were observed. In conclusion, the above high-dose IV iron sucrose supplementation does not cause evident endothelial or other tissue injury in patients with CRF, and is clinically safe...
  14. ncbi Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients
    Krystyna Pawlak
    Department of Nephrology and Internal Medicine, Medical University of Bialystok, 14 Zurawia Street, 15 540 Bialystok, Poland
    Thromb Res 109:247-51. 2003
    ....
  15. ncbi Effect of hemodialysis on plasma levels of vascular endothelial markers
    Beata Naumnik
    Department of Nephrology and Internal Medicine, Medical Academy, , Poland
    Clin Appl Thromb Hemost 8:245-50. 2002
    ..The release of tissue factor pathway inhibitor during HD is not only due to heparin injection but also to the contact between blood and artificial dialysis membrane, and to HD-activated hemodynamic forces...
  16. ncbi Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study
    Beata Naumnik
    Department of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland
    Nephrol Dial Transplant 18:1376-82. 2003
    ..The traditional UFH regimen is more prothrombotic than single enoxaparin injections, with high loading doses of UFH being involved in TFPI exhaustion and subsequent hypercoagulability...
  17. ncbi Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins
    Alicja Rydzewska-Rosołowska
    Department of Nephrology and Transplantation, Medical University of Białystok, Białystok, Poland
    Ren Fail 31:791-7. 2009
    ..Moreover, the concentrations of HGF/Act A/FS are close to therapeutic ones, which may partly explain the mechanisms underlying some of the emerging extra-anticoagulant effects of LMWHs...
  18. ncbi Hepatocyte growth factor in saliva is a potential marker of symptomatic periodontal disease
    Magdalena Wilczynska-Borawska
    Department of Stomatology and Periodontics, Medical University, Bialystok, Poland
    J Oral Sci 48:47-50. 2006
    ..351), CAL loss (P = 0.172), number of teeth (P = 0.279) or patient age (P = 0.362). Our findings suggest that salivary HGF concentration may be a novel marker of symptomatic periodontal disease, and that it warrants further validation...
  19. ncbi Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Bialystok, Poland
    Clin Appl Thromb Hemost 8:77-84. 2002
    ..In conclusion, short-term rHuEpo therapy activates vascular endothelium in patients receiving maintenance hemodialysis. This specific effect may influence cardiovascular risk...
  20. ncbi Sulodexide induces hepatocyte growth factor release in humans
    Jacek Borawski
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University, 14 Zurawia St, 15 540 Bialystok, Poland
    Eur J Pharmacol 558:167-71. 2007
    ..v. sulodexide dose per kg of body weight. This study shows that sulodexide has a novel, remarkable and plausibly biologically important stimulating effect on the release of pleiotropic hepatocyte growth factor in humans...
  21. ncbi Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients
    Krystyna Pawlak
    Department of Monitored Pharmacotherapy, Medical University, Bialystok, Poland
    Thromb Res 123:166-70. 2008
    ..The aim of the present study was to establish whether the presence of chronic viral hepatitis (PVH) could be implicated in the elevation of oxidative stress (SOX) and haemostasis system in haemodialysis (HD) patients...
  22. ncbi Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study
    Beata Naumnik
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University, 14 Zurawia Street, 15 540 Białystok, Poland
    Nephrol Dial Transplant 22:1690-6. 2007
    ....
  23. ncbi Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Biakystok, Poland
    Nephrol Dial Transplant 17:637-44. 2002
    ..We studied which of the common co-morbid and clinical conditions, and surrogates of metabolic disorders or specific organ damage determine HGF levels in these subjects...
  24. ncbi Pleiotropic effects of heparin and heparinoids in peritoneal dialysis
    Joanna Gozdzikiewicz
    Department of Nephrology and Transplantation with Dialysis Unit, Medical University, Bialystok, Poland
    Clin Appl Thromb Hemost 15:92-7. 2009
    ..These issues, novel medical approaches, and their likely mechanisms have been reviewed...
  25. ncbi Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels
    Beata Naumnik
    Department of Nephrology and Transplantology with Dialysis Unit, Medical University, 14 Zurawia St, 15 549 Biatystok, Poland
    Nephrol Dial Transplant 21:3450-7. 2006
    ..We studied the relationship between plasma and urinary levels as well as renal biopsy immunostaining of TF and TFPI antigens with reference to some clinical parameters in human chronic non-crescentic GN...
  26. ncbi Hemoglobin level is an important determinant of acid-base status in hemodialysis patients
    Jacek Borawski
    Department of Nephrology and Internal Medicine, Medical Academy, Białystok, Poland
    Nephron 90:111-3. 2002
    ..We also evaluated the difference between the tCO2 measured with a standard Hb value of 15 g/dl, and that assayed with an actual Hb level entered into an analyzer...
  27. ncbi Staphylococcal scalded skin syndrome in the course of lupus nephritis
    Alicja Rydzewska-Rosołowska
    Departament of Nephrology and Transplantation with Dialysis Unit, Bialystok, Poland
    Nephrology (Carlton) 13:265-6. 2008
  28. ncbi Hepatocyte growth factor in saliva of patients with renal failure and periodontal disease
    Magdalena Wilczynska-Borawska
    Department of Conservative Dentistry, Medical University of Bialystok, Białystok, Poland
    Ren Fail 34:942-51. 2012
    ..Furthermore, PD is a significant health problem in patients with chronic renal failure (CRF). The role of HGF in the development of PD in this specific population was not a subject of research so far...
  29. ncbi Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy
    Irina Kowalska
    Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Białystok, ul M C Skłodowskiej 24a, 15 276, Białystok, Poland
    Endocrine 40:95-101. 2011
    ..01), whereas adiponectin concentration remained unchanged. We concluded that L-thyroxine treatment in patients with subclinical hypothyroidism might exert a beneficial effect by reducing cardiovascular risk factors...
  30. ncbi Increased soluble thrombomodulin does not always indicate endothelial injury
    Jacek Borawski
    Clin Appl Thromb Hemost 8:87-9. 2002
  31. ncbi Circulating endothelial markers and probability of stroke in haemodialysis patients
    Jacek Borawski
    Blood Coagul Fibrinolysis 14:315-7. 2003
  32. ncbi Renal function, proteinuria and ACE-inhibitor therapy as determinants of plasma levels of endothelial markers
    Beata Naumnik
    Nephrol Dial Transplant 17:526-8. 2002
  33. ncbi Hepatocyte growth factor: a possible mediator of heparin-induced osteoporosis?
    Jacek Borawski
    Clin Appl Thromb Hemost 9:171-2. 2003
  34. ncbi Treatment of heparin-induced thrombocytopenia type II in hemodialysis patients: the search for a Holy Grail continues
    Joanna Gozdzikiewicz
    Clin Appl Thromb Hemost 13:110-1. 2007
  35. ncbi Liver disease vs systemic inflammation in haemodialysis patients
    Jacek Borawski
    Nephrol Dial Transplant 20:1277-8. 2005
  36. ncbi Activin A/follistatin system: another link to heparin-induced osteoporosis?
    Jacek Borawski
    Clin Appl Thromb Hemost 10:191-2. 2004
  37. ncbi [Evaluation of the thyroid size among school children aged 6-13 with the normal iodine excretion in the urine and the usability of referential values still applied]
    Adam Kretowski
    Klinika Endokrynologii,
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 11:229-36. 2005
    ..The prevalence of goiter amounting 7% in the population of school children in spite of adequate iodine prophylaxis suggests other than iodine deficit, factors causing goiter in this population...
  38. ncbi [Activin A-follistatin: new cytokines, new perspectives]
    Beata Naumnik

    Pol Arch Med Wewn 109:431-5. 2003
  39. ncbi Myeloperoxidase up-regulation during haemodialysis: is heparin the missing link?
    Jacek Borawski
    Nephrol Dial Transplant 21:1128; author reply 1128-30. 2006
  40. ncbi Striking increase in circulating hepatocyte growth factor during enoxaparin-anticoagulated haemodialysis
    Jacek Borawski
    Nephrol Dial Transplant 18:1680-2. 2003
  41. ncbi Unexpected effect of haemodialysis on salivary hepatocyte growth factor
    Magdalena Wilczynska-Borawska
    Nephrol Dial Transplant 20:2869-70. 2005
  42. ncbi TGF-beta1 and endothelial/tissue injury with high-dose intravenous iron therapy in renal failure: evidence or perception?
    Joanna Gozdzikiewicz
    Clin Appl Thromb Hemost 12:493-4. 2006
  43. ncbi Short-term erythropoietin therapy does not increase plasma tissue factor and its inhibitor levels in hemodialysis patients
    Jacek Borawski
    Clin Appl Thromb Hemost 9:173-4. 2003
  44. ncbi [Relevance of some growth factors to cardiovascular disease in maintenance hemodialysis patients]
    Jacek Borawski
    ,
    Pol Merkur Lekarski 21:117-8; discussion 119. 2006
    ....
  45. ncbi Plasma activin A in hemodialysis patients: does brand of immunoassay matter?
    Jacek Borawski
    Kidney Int 66:465. 2004
  46. ncbi Heparin, myeloperoxidase, and atherosclerosis: a new focus on an old drug
    Jacek Borawski
    Clin Appl Thromb Hemost 13:219-20. 2007